GSK readying Ebola vax; Former FDA critic now big supporter; Pfizer fights Benadryl price cut in India;

@FiercePharma: Top-read on FP this weekend: Pfizer faces growing legal threat over Lipitor. Article | Follow @FiercePharma

@EricPFierce: ICYMI last week: Instead of buying counterfeit Viagra from China, this guy bought APIs and whipped up an ED drug in his home lab. More | Follow @EricPFierce

@CarlyHFierce: Favorite fact I've learned so far today: The inhaler for MannKind's Afrezza inhaler is named "Dreamboat." | Follow @CarlyHFierce

> The FDA has approved Johnson & Johnson's ($JNJ) Invokamet, a combination of its diabetes drug Invokana and metformin. Story

> Vax leader GlaxoSmithKline ($GSK) says it will soon start a clinical trial for a vaccine for the lethal Ebola virus. Story

> Cubist Pharmaceuticals ($CBST) has expanded its recall of anti-infection drug Cubicin to 9 lots because of particulate matter found in some vials. Release

> Gregg Gonsalves, who was a big critic of the FDA in the 1990s in his fight for drugs to treat AIDS, is now defending the agency against what he considers anti-regulatory sentiment. Story

Medical Device News

@FierceMedDev: ICYMI: Volcano guides lower but offers long-term vision, Wall Street trims by as much as 25%. Article | Follow @FierceMedDev

@StacyALawrence: Med tech M&A gets much, much bigger during the first half. Feature | Follow @StacyALawrence

@VarunSaxena2: RT @foodanddruglaw: CMS delays launch of Sunshine Act reporting website. More from The Hill | Follow @VarunSaxena2

@MichaelGFierce: Carnegie Mellon team creates self-assembling nanofibers for shaped delivery vehicles. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Not for the faint of heart: A behind-the-scenes look at creating prosthetic eyes. More from NPR | Follow @EmilyWFierce

> Medtronic hires former senators to lobby against anti-inversion bill and protect acquisition of Covidien. Report

> Imaging pen may detect skin cancer faster. More

Biotech News

@FierceBiotech: Can GlaxoSmithKline go from 0 to 150 on an Ebola vaccine program? Story | Follow @FierceBiotech

@JohnCFierce: ICYMI last week: How big is Novartis's LCZ696 heart drug? Experts bet on a key number. More | Follow @JohnCFierce

@DamianFierce: $MNKD finally gets its Afrezza deal as $SNY signs up for $150M up front and $775M in milestones. Article | Follow @DamianFierce

> Forward Pharma sets sights on Biogen with a $200M IPO. Article

> J&J's diabetes combo wins FDA nod in a fast-crowding space. News

> Google sheds glancing light on Calico, its anti-aging biotech. More

CRO News

> Icon charts another sales jump with eyes on a big year. Report

> Charles River's checkbook fuels a leap in revenue. More

> Quintiles and Roche take to China with testing partnership. News

> Parexel notches double-digit annual growth with a big year ahead. Article

> Deal-minded Venn buys another CRO. Story

Biotech IT News

> Actelion working with PatientsLikeMe rare cancer community on outcome measure. Report

> U.S. research institutes target standard neuroscience data format. More

> AllSeq, DNAnexus share data from Illumina HiSeq X Ten. Story

> Google rolls out preview of healthcare app development kit. Article

> The race to build a robo-chemist. Item

Animal Health News

> Cost spike of doxycycline has created sticker shock for pet owners. Report

> Zoetis CEO sees global factors coalescing to spur more growth. More

> Medical marijuana coming to the pet med market. Item

> SmartPak acquisition helps Henry Schein grow its animal health sales. Story

> Zoetis expects to have PEDv vaccine ready this year. Article

And Finally... The fight over the price Pfizer ($PFE) can charge in India for its popular cough syrup Benadryl continues. Report

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.